Sphera Funds Management’s Altimmune ALT Stock Holding History

Sphera Funds Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-500,000	Closed	-$1.76M	–	84
2023 Q2	$1.76M	Buy	500,000 +200,000	+67%	+$898K	0.28%	73
2023 Q1	$1.27M	Sell	300,000 -80,298	-21%	-$954K	0.21%	68
2022 Q4	$6.26M	Sell	380,298 -220,000	-37%	-$2.47M	1.34%	26
2022 Q3	$7.67M	Sell	600,298 -792,586	-57%	-$11.7M	1.06%	29
2022 Q2	$16.3M	Buy	1,392,884 +85,931	+7%	+$530K	1.74%	13
2022 Q1	$7.96M	Buy	1,306,953 +62,712	+5%	+$462K	1.12%	25
2021 Q4	$11.4M	Buy	1,244,241 +155,387	+14%	+$1.65M	1.25%	26
2021 Q3	$12.3M	Buy	1,088,854 +405,459	+59%	+$4.93M	1.03%	22
2021 Q2	$6.73M	Buy	+683,395	New	+$9.34M	0.46%	62
2020 Q4	–	Sell	-243,000	Closed	-$3.21M	–	112
2020 Q3	$3.21M	Buy	+243,000	New	+$4.86M	0.32%	71

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Sphera Funds Management's ALT Position: Q3 2023 in Review

Sphera Funds Management sold out of Altimmune (ALT) in Q3 2023, closing a stake of 500,000 shares — an estimated $1.76M sold.

Sphera Funds Management first reported a position in ALT in Q3 2020 and held it in 10 quarters. The position peaked at $16.3M in Q2 2022. 112 funds tracked by Wall St. Rank hold ALT as of Q3 2023.

Sphera Funds Management reported no remaining Altimmune position as of Q3 2023 after selling out during the quarter.
Sphera Funds Management sold 500,000 Altimmune shares in Q3 2023, an estimated $1.76M.
Sphera Funds Management first reported a position in Altimmune in Q3 2020 and held it in 10 quarters.
Sphera Funds Management's Altimmune position peaked at $16.3M in Q2 2022.
112 funds tracked by Wall St. Rank held Altimmune as of Q3 2023.

Based on Sphera Funds Management's 13F filing for Q3 2023, filed 14 Nov 2023.